DexCom Board Member's Planned Stock Sale Follows Recent RSU Grant

Rhea-AI Filing Summary

DexCom Director Mark G. Foletta reported significant insider trading activity through a pre-planned 10b5-1 sale. On June 16, 2025, Foletta's Family Trust sold 2,750 shares at a weighted average price of $83.129 per share, executed through multiple trades ranging from $82.635 to $83.61.

Following the transaction, Foletta maintains beneficial ownership of:

• 56,621 shares held indirectly through The Foletta Family Trust DTD 1/30/2015
• 5,731 unvested restricted stock units granted on May 8, 2025, which will vest on the earlier of the one-year anniversary or DexCom's 2026 Annual Meeting

The sale was executed under a 10b5-1 trading plan adopted by the Trust on March 13, 2025, designed to enable orderly disposition of shares. This transaction demonstrates planned insider selling activity while maintaining substantial equity position in the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOLETTA MARK G

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2025		S		2,750(1)	D	$83.129(2)	56,621	I	by Trust(3)
Common Stock								5,731(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 13, 2025, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.

2. This transaction was executed in multiple trades at prices ranging from $82.635 to $83.61. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

3. Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the reporting person is a trustee.

4. Represents unvested restricted stock units which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Mark G. Foletta	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many DXCM shares did Director Mark Foletta sell on June 16, 2025?

Director Mark Foletta, through The Foletta Family Trust, sold 2,750 shares of DexCom (DXCM) common stock at an average price of $83.129 per share on June 16, 2025.

What is the current DXCM stock ownership of Mark Foletta after the June 2025 transaction?

Following the reported transaction, Mark Foletta owns 56,621 shares indirectly through The Foletta Family Trust and 5,731 shares directly in the form of unvested restricted stock units (RSUs).

Was DXCM Director Foletta's stock sale part of a 10b5-1 trading plan?

Yes, the sale was executed under a 10b5-1 Plan that The Foletta Family Trust adopted on March 13, 2025. This plan was established to allow for orderly disposition of shares owned by the Trust.

When will Mark Foletta's DXCM restricted stock units (RSUs) vest?

The 5,731 RSUs, which were granted on May 8, 2025, will vest on the earlier of either the one-year anniversary of the grant date or the date of DexCom's 2026 Annual Meeting of Stockholders.

What was the price range of DXCM shares sold by Director Foletta in June 2025?

The shares were sold in multiple trades at prices ranging from $82.635 to $83.61, with a weighted average sale price of $83.129 per share.